MétaCan
Menu
← Back to cohort

Prognostic immune scoring of colorectal cancer liver metastasis with MHC class-I expression combined to T cell quantification.

2018· article· en· W2890571864 on OpenAlexaff
David Henault, David Stephen, Pierre-Antoine St-Hilaire, Nouredin Messaoudi, Franck Vandenbroucke‐Menu, M. Plasse, Richard Létourneau, André Roy, M. Dagenais, Réal Lapointe, Bich Nguyen, Geneviève Soucy, Anne‐Marie Mes‐Masson, Simon Turcotte

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsMedicineColorectal cancerCD8Immune systemChemotherapyMajor histocompatibility complexTissue microarrayMetastasisImmunohistochemistryInternal medicineOncologyGastroenterologyPathologyCancerImmunology

Abstract

fetched live from OpenAlex

3586 Background: Approximately 80% of patients recur after curative-intent resection of colorectal cancer liver metastasis (CRLM) and systemic chemotherapy. Immune profiling may help prognostication to individualize follow-up and lead to novel therapeutic strategies. We tested whether adding major histocompatibility class I (MHC-I) expression to T cell immune scoring in CRLMs could group patients with distinct prognosis. Methods: Tissue microarray analysis of 391 CRLMs resected in 214 patients (2011-2014) followed prospectively until 10/2017. Each CRLM arrayed with twelve 0.6 mm punch biopsies, 6 at the interface (IF) with normal liver and 6 intratumoral (IT). Automated quantification of CD3+ cells and MHC-I+ surface area stained by immunohistochemistry. We tested associations between immune, clinicopathological, and time to recurrence (TTR) and disease specific survival (DSS) outcome variables. Results: The mean patient age was 62.7 years, 78.5% received pre-operative chemotherapy (mean of 6 cycles), and a median of 2 CRLMs/patient were resected. The median TTR and DSS were 15.4 and 56.7 months, respectively. Pre-operative chemotherapy was associated with higher CD3 infiltration and lower MHC-I expression at IF and IT. Good pathological response to chemotherapy (Rubbia-Brandt TRG score 1-2-3) compared to lack of response (TRG 4-5) was associated with higher CD3 infiltration but no significant difference in MHC-I expression. CD3 immune scoring integrating the IF and IT areas had no prognostic value. MHC-I expression prognostically stratified patients with CD3low but not CD3high CRCLMs. Compared to the rest of the cohort, patients with at least one CD3lowMHC-Ihi CRLM (n = 35, 16.4 %) had significantly shorter median TTR (8.3 vs. 17.1 months, p < 0.001) and DSS (42.6 vs. 61.5 months, p < 0.001). CD3lowMHC-Ihi CRLMs were found in 41.2% of recurrent CRLMs in patients without this type of metastasis at first resection. CD3lowMHC-Ihi CRLM was an independent predictor of poor outcomes by multivariate analysis. Conclusions: CD3lowMHChi CRLMs may identify patients with poorly immunogenic tumors associated with worst outcome and suboptimal response to systemic chemotherapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.110
GPT teacher head0.437
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→